An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis

Rhinitis, Allergic, Perennial Clinical Trial

Official title:

An Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD Children Ages 2-5 Years With Perennial Allergic Rhinitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00132925
• Other study ID #: XRG5029C_3502
• Status: Completed
• Phase: Phase 3
• First received: August 18, 2005
• Last updated: January 10, 2011
• Start date: November 2003
• Est. completion date: February 2006

Study information

• Verified date: January 2011
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purposes of this study are:

• To demonstrate the efficacy of once daily administration of Nasacort AQ 110 µg compared with placebo in children 2-5 years of age with perennial allergic rhinitis; and

• To assess the safety of Nasacort AQ 110 µg in children 2-5 years of age.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 460
• Est. completion date: February 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Years to 5 Years

Eligibility

Inclusion Criteria:

• Subjects will be male or female children ages 2-5 years with a history of at least 1 year of perennial allergic rhinitis (PAR) with or without seasonal allergic rhinitis (SAR) characterized by nasal stuffiness, nasal discharge, sneezing, nasal itching, and total eye symptoms, and verified by positive skin test or radioallergosorbent test (RAST) to perennial allergen that is present in the subject's environment (documented historical testing performed during the past year will be accepted).

• Subjects (assisted by a parent/guardian/care provider) must meet an aggregate symptom score of at least 18 (out of a possible 36) for nasal stuffiness, nasal discharge and sneezing for both the reflective (previous 24 hours) and instantaneous symptom scores recorded in the morning

• Subjects must not have clinically relevant disease other than allergic rhinitis or have clinically relevant deviations from normal on a physical examination.

• Subjects must not have been recently exposed to rhinitis medications prior to screening

• Subjects must have no history of hypersensitivity to glucocorticoids or to any excipients of the formulation

• Subjects undergoing cosyntropin stimulation test must have a morning (8 AM ± 1 hour) pre-stimulation serum cortisol level = 5 µg/dL and 30 minutes post-stimulation serum cortisol level = 18 µg/dL at screening

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

• Asthma, requiring chronic use of inhaled or systemic corticosteroids in the previous 6 months; upper respiratory tract infection or sinus infection requiring antibiotic therapy within 2 weeks prior to screening or viral upper respiratory tract infection within 7 days of screening.

• Nasal polyps, deviated septum, or nasal/facial anatomic abnormalities that interfere with symptom evaluation and/or use of intranasal corticosteroids

• Treatment with more than 2 courses of systemic corticosteroids (each course not exceeding 14 days) within 1 year of screening

• Use of intranasal or ocular corticosteroids within 2 weeks of screening

• Use of oral, inhaled, or intravenous corticosteroids within 1 month of screening

• Use of intramuscular or intra-articular corticosteroids within 3 months of screening

• Use of high potency dermatological corticosteroids within 1 month of screening

• Use of oral leukotriene modifiers within 1 week of screening

• Use of nasal or oral antihistamines or oral or nasal decongestants within 3 days of screening

• Current or history of cataract or glaucoma

• Treatment with any investigational product or use of an investigational device within 1 month of screening

• Immunotherapy, with the exception of a stable maintenance schedule, for at least 1 month prior to screening

• History of hypersensitivity to glucocorticoids or to any excipients of the formulation

• Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof directly involved in the conduct of the protocol.

Any waiver of these inclusion and exclusion criteria must be approved by the investigator and the sponsor on a case-by-case basis prior to enrolling the subject. This must be documented by both the sponsor and the investigator.

No subject will be allowed to enroll in this study more than once.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Rhinitis
• Rhinitis, Allergic, Perennial

Intervention

Drug:
• Triamcinolone

Locations

Country	Name	City	State
United States	Sanofi-Aventis, Inc.	Bridgewater	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Double-blind phase: Change from baseline in mean daily instantaneous (immediately prior to dosing) Total Nasal Symptom Score (TNSS) over the 4-week double-blind period
Primary	Open-label phase: The efficacy variable is the global evaluation of efficacy as rated by the physician and the subject
Secondary	Change from baseline: in mean daily reflective (previous 24 hours) TNSS over 4-wk double-blind period
Secondary	for mean daily instantaneous and reflective TNSS by week
Secondary	for mean instantaneous and reflective daily scores for nasal stuffiness, nasal discharge, sneezing, nasal itching, and total eye symptoms by week and over four week double-blind period